MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Influence of baseline OFF-time in the efficacy response of Parkinson’s disease patients with motor fluctuations: post-hoc analysis from combined BIPARK-I and II

    A. Santos, J. Ferreira, A. Lees, H. Reichmann, W. Poewe, F. Ikedo, D. Magalhães, J. Rocha, P. Soares-da-Silva (Coronado, Portugal)

    Objective: To evaluate the impact of baseline OFF-time on the efficacy of opicapone (OPC) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations. Background: OPC,…
  • 2019 International Congress

    An open-label, 1-year extension clinical study in Japan of Opicapone treatment for Parkinson’s disease -Comfort-PD study part 2

    A. Takeda, R. Takahashi, Y. Tsuboi, M. Nomoto, T. Maeda, A. Nishimura, N. Hattori (Sendai, Japan)

    Objective: To investigate the safety and efficacy of continuous treatment with 50 mg Opicapone (OPC) for 1 year after treatment with a placebo, 25 mg…
  • 2019 International Congress

    INTREPID: A 2-Year Follow-Up of a Prospective, Double Blinded, Multi-Center Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant-Current Rechargeable System for Treatment of Parkinson’s Disease

    J. Vitek, R. Jain, L. Chen, I. Study Group, P. Starr (Minneapolis, MN, USA)

    Objective: The objective of the INTREPID clinical trial assessed improvement in motor function and quality of life in patients with advanced, levodopa responsive Parkinson's disease…
  • 2019 International Congress

    Brain MRI-based discrimination between multiple system atrophy type cerebellar from other late onset sporadic cerebellar ataxias: a prospective study with implications for diagnosis criteria

    G. Carré, JL. Dietemann, O. Gebus, S. Montaut, O. Lagha-Boukbiza, T. Wirth, S. Kremer, IJ. Namer, M. Anheim, C. Tranchant (Strasbourg, France)

    Objective: To evaluate, in patients with sporadic late-onset cerebellar ataxia (SLOCA), the discriminative value of each of the magnetic resonance imaging (MRI) features for the…
  • 2019 International Congress

    Normative Reference for Timed Up and Go Test (TUG) in Young Indian Adults- Preliminary Results

    D. Kaur, K. Umakant, T. Aziz, P. Jaiswal, M. Kumari, A. Gupta, G. Kumar (Patna, India)

    Objective: This study investigated the clinical usefulness of the time up and go test in young population and provide a reference range for healthy adults.…
  • 2019 International Congress

    Non-CpG methylation in the FXN gene in patients with Friedreich’s ataxia

    E. Nuzhnyi, N. Abramycheva, M. Ershova, S. Klyushnikov, N. Nikolaeva, S. Illarioshkin, E. Fedotova (Moscow, Russian Federation)

    Objective: To compare methylation profiles of non-CpG sites in the FXNgene in patients with Friedreich’s ataxia (FA), their heterozygous relatives and a healthy control group. Background: FA is…
  • 2019 International Congress

    Alcohol- Induced Cerebellar Ataxia

    B. Zeigelboim, H. Teive, C. Santos Junior, J. Malisky, M. da Rosa, R. Sampaio, M. José (Curitiba, Brazil)

    Objective: To verify vestibulocochlear disorders observed in a case of alcohol-induced cerebellar ataxia. Background: Alcohol-induced cerebellar degeneration is the commonest type of acquired toxic ataxia,…
  • 2019 International Congress

    Sydenham’s chorea: Clinical features and treatment outcome

    S. Pandey, P. Rani (New Delhi, India)

    Objective: To study the clinical features, investigations and treatment outcome in Sydenham’s chorea patients. Background: Sydenham’s chorea is one of the major clinical manifestations of…
  • 2019 International Congress

    The short-term effect of combined facial exercise with botulinum toxin A injection in clinical practice in Thai patients with hemifacial spasm: A randomized controlled pilot crossover study

    P. Soontrapa, Y. Pitakpatapee, A. Suengtaworn, J. Srikajon, T. Sangpeamsook, P. Srivanitchapoom (Bangkok, Thailand)

    Objective: To compare the efficacy of combined facial exercise with BTX-A injection with BTX-A injection alone measured by the total HFS-30 (tHFS-30) score. Background: Hemifacial…
  • 2019 International Congress

    The mGlu2/3 orthosteric antagonist LY-341,495 abolishes the anti-dyskinetic and anti-psychotic effects of the mGlu2 positive allosteric modulator LY-487,379 in the MPTP-lesioned marmoset

    A. Hamadjida, S. Nuara, J. Gourdon, P. Huot (Montreal, QC, Canada)

    Objective: We seek to determine the effect of orthosteric blockade of metabotropic glutamate 2 and 3 (mGlu2/3) receptors with LY-341,495 on the anti-dyskinetic and anti-psychotic…
  • « Previous Page
  • 1
  • …
  • 122
  • 123
  • 124
  • 125
  • 126
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley